{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:03:30Z","timestamp":1789473810151,"version":"build-2803163510"},"reference-count":266,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40257-026-01054-x","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:34:23Z","timestamp":1782711263000},"page":"997-1025","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Atopic Dermatitis: New Targets and Emerging Systemic Therapies"],"prefix":"10.1007","volume":"27","author":[{"given":"Gianluca","family":"Avallone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Beaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Manzo Margiotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Del Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"10478","key":"1054_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","volume":"405","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet Lond Engl. 2025;405(10478):583\u201396.","journal-title":"Lancet Lond Engl."},{"issue":"12","key":"1054_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"S St\u00e4nder","year":"2021","unstructured":"St\u00e4nder S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136\u201343.","journal-title":"N Engl J Med"},{"issue":"Suppl 7","key":"1054_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jdv.18168","volume":"36","author":"M Augustin","year":"2022","unstructured":"Augustin M, Misery L, von Kobyletzki L, Armario-Hita JC, Mealing S, Redding M. Unveiling the true costs and societal impacts of moderate-to-severe atopic dermatitis in Europe. J Eur Acad Dermatol Venereol JEADV. 2022;36(Suppl 7):3\u201316.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"2","key":"1054_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/jdv.19500","volume":"38","author":"K Eyerich","year":"2024","unstructured":"Eyerich K, Gooderham MJ, Silvestre JF, Shumack SP, Mendes-Bastos P, Aoki V, et al. Real-world clinical, psychosocial and economic burden of atopic dermatitis: results from a multicountry study. J Eur Acad Dermatol Venereol JEADV. 2024;38(2):340\u201353.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"key":"1054_CR5","unstructured":"AAAAI\/ACAAI JTF Atopic Dermatitis Guideline Panel, Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2024;132(3):274\u2013312."},{"issue":"6","key":"1054_CR6","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jaci.2023.08.030","volume":"152","author":"DK Chu","year":"2023","unstructured":"Chu DK, Chu AWL, Rayner DG, Guyatt GH, Yepes-Nu\u00f1ez JJ, Gomez-Escobar L, et al. Topical treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023;152(6):1493\u2013519.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"1054_CR7","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1001\/jama.2025.11589","volume":"334","author":"AM Drucker","year":"2025","unstructured":"Drucker AM. Treatment of atopic dermatitis. JAMA. 2025;334(12):1103\u20134.","journal-title":"JAMA"},{"issue":"1","key":"1054_CR8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","volume":"89","author":"R Sidbury","year":"2023","unstructured":"Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):e1-20.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1054_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","volume":"84","author":"AS Halling","year":"2021","unstructured":"Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139\u201347.","journal-title":"J Am Acad Dermatol"},{"issue":"3 Suppl 1","key":"1054_CR10","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","volume":"78","author":"MJ Gooderham","year":"2018","unstructured":"Gooderham MJ, Hong HCH, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3 Suppl 1):S28-36.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1054_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130\u20139.","journal-title":"N Engl J Med"},{"key":"1054_CR12","doi-asserted-by":"publisher","first-page":"1342810","DOI":"10.3389\/fimmu.2024.1342810","volume":"15","author":"Q He","year":"2024","unstructured":"He Q, Xie X, Chen Q, Li W, Song Z, Wang X, et al. Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses. Front Immunol. 2024;15:1342810.","journal-title":"Front Immunol"},{"issue":"2","key":"1054_CR13","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43-56.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1054_CR14","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s40265-024-02095-4","volume":"84","author":"JM Alvarenga","year":"2024","unstructured":"Alvarenga JM, Bieber T, Torres T. Emerging biologic therapies for the treatment of atopic dermatitis. Drugs. 2024;84(11):1379\u201394.","journal-title":"Drugs"},{"issue":"2","key":"1054_CR15","first-page":"135","volume":"34","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Mohawk JA, Cirulli J, Nograles K, Punzalan JC, Kelly KM, et al. Burden of disease and unmet needs in atopic dermatitis: results from a patient survey. Dermat Contact Atopic Occup Drug. 2023;34(2):135\u201344.","journal-title":"Dermat Contact Atopic Occup Drug."},{"issue":"9","key":"1054_CR16","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1007\/s13555-024-01253-6","volume":"14","author":"O Yilmaz","year":"2024","unstructured":"Yilmaz O, Torres T. Extended half-life antibodies: a narrative review of a new approach in the management of atopic dermatitis. Dermatol Ther. 2024;14(9):2393\u2013406.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1054_CR17","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/all.16009","volume":"79","author":"S M\u00fcller","year":"2024","unstructured":"M\u00fcller S, Maintz L, Bieber T. Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs. Allergy. 2024;79(6):1501\u201315.","journal-title":"Allergy"},{"key":"1054_CR18","doi-asserted-by":"crossref","unstructured":"de Bruin-Weller MS, Boesjes CM, Achten RA, Beck LA, Irvine AD, Vestergaard C, et al. Biologics to treat atopic dermatitis: effectiveness, safety, and future directions. Allergy. 2026;81(2):326\u2013344.","DOI":"10.1111\/all.70061"},{"issue":"10247","key":"1054_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet Lond Engl. 2020;396(10247):345\u201360.","journal-title":"Lancet Lond Engl."},{"key":"1054_CR20","doi-asserted-by":"crossref","unstructured":"Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338\u201351.","DOI":"10.1016\/j.jaad.2013.10.010"},{"issue":"4","key":"1054_CR21","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","volume":"134","author":"DYM Leung","year":"2014","unstructured":"Leung DYM, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134(4):769\u201379.","journal-title":"J Allergy Clin Immunol"},{"issue":"14","key":"1054_CR22","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1056\/NEJMra1011040","volume":"365","author":"AD Irvine","year":"2011","unstructured":"Irvine AD, McLean WHI, Leung DYM. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14):1315\u201327.","journal-title":"N Engl J Med"},{"issue":"5","key":"1054_CR23","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.jid.2023.10.019","volume":"144","author":"CF Schuler","year":"2024","unstructured":"Schuler CF, Tsoi LC, Billi AC, Harms PW, Weidinger S, Gudjonsson JE. Genetic and immunological pathogenesis of atopic dermatitis. J Invest Dermatol. 2024;144(5):954\u201368.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1054_CR24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jid.2024.03.006","volume":"144","author":"M Schmuth","year":"2024","unstructured":"Schmuth M, Eckmann S, Moosbrugger-Martinz V, Ortner-Tobider D, Blunder S, Trafoier T, et al. Skin barrier in atopic dermatitis. J Invest Dermatol. 2024;144(5):989-1000.e1.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1054_CR25","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaci.2012.12.1563","volume":"131","author":"IH Kuo","year":"2013","unstructured":"Kuo IH, Yoshida T, De Benedetto A, Beck LA. The cutaneous innate immune response in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131(2):266\u201378.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"1054_CR26","doi-asserted-by":"publisher","first-page":"e1141","DOI":"10.1111\/jdv.19153","volume":"37","author":"M Michaelidou","year":"2023","unstructured":"Michaelidou M, Redhu D, Kumari V, Babina M, Worm M. IL-1\u03b1\/\u03b2 and IL-18 profiles and their impact on claudin-1, loricrin and filaggrin expression in patients with atopic dermatitis. J Eur Acad Dermatol Venereol JEADV. 2023;37(9):e1141\u20133.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"5","key":"1054_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000515144","volume":"182","author":"NL Bertschi","year":"2021","unstructured":"Bertschi NL, Bazzini C, Schlapbach C. The concept of pathogenic TH2 cells: collegium internationale allergologicum update 2021. Int Arch Allergy Immunol. 2021;182(5):365\u201380.","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"1054_CR28","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jaci.2025.07.025","volume":"156","author":"L B\u00e4hler","year":"2025","unstructured":"B\u00e4hler L, Sch\u00e4rli S, Luther F, Bertschi NL, Skabytska Y, Roediger B, et al. IL-18 in atopic dermatitis-a multifaceted driver of skin inflammation. J Allergy Clin Immunol. 2025;156(5):1160\u201372.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1054_CR29","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/bjd\/ljae230","volume":"191","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Croft M, Geng B, Rynkiewicz N, Lucchesi D, Peakman M, et al. The role of OX40 ligand\/OX40 axis signalling in atopic dermatitis. Br J Dermatol. 2024;191(4):488\u201396.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1054_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","volume":"15","author":"NA Gandhi","year":"2016","unstructured":"Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35\u201350.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"1054_CR31","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/ni1084","volume":"5","author":"SR Dillon","year":"2004","unstructured":"Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5(7):752\u201360.","journal-title":"Nat Immunol"},{"key":"1054_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","volume":"48","author":"E Guttman-Yassky","year":"2017","unstructured":"Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Curr Opin Immunol. 2017;48:68\u201373.","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"1054_CR33","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nri2580","volume":"9","author":"Y Rochman","year":"2009","unstructured":"Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol. 2009;9(7):480\u201390.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"1054_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","volume":"20","author":"H He","year":"2019","unstructured":"He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181\u201392.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1054_CR35","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","volume":"20","author":"P Facheris","year":"2023","unstructured":"Facheris P, Jeffery J, Del Duca E, Guttman-Yassky E. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol. 2023;20(5):448\u201374.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"1054_CR36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaci.2020.06.012","volume":"147","author":"L M\u00f6bus","year":"2021","unstructured":"M\u00f6bus L, Rodriguez E, Harder I, St\u00f6lzl D, Boraczynski N, Gerdes S, et al. Atopic dermatitis displays stable and dynamic skin transcriptome signatures. J Allergy Clin Immunol. 2021;147(1):213\u201323.","journal-title":"J Allergy Clin Immunol"},{"issue":"23","key":"1054_CR37","doi-asserted-by":"publisher","first-page":"15942","DOI":"10.1074\/jbc.M114.557561","volume":"289","author":"H England","year":"2014","unstructured":"England H, Summersgill HR, Edye ME, Rothwell NJ, Brough D. Release of interleukin-1\u03b1 or interleukin-1\u03b2 depends on mechanism of cell death. J Biol Chem. 2014;289(23):15942\u201350.","journal-title":"J Biol Chem"},{"key":"1054_CR38","first-page":"52","volume":"20","author":"V Kumar","year":"2021","unstructured":"Kumar V. Going, Toll-like receptors in skin inflammation and inflammatory diseases. EXCLI J. 2021;20:52\u201379.","journal-title":"EXCLI J"},{"issue":"1","key":"1054_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1085\/jgp.201311083","volume":"143","author":"M Conti","year":"2014","unstructured":"Conti M, Mika D, Richter W. Cyclic AMP compartments and signaling specificity: role of cyclic nucleotide phosphodiesterases. J Gen Physiol. 2014;143(1):29\u201338.","journal-title":"J Gen Physiol"},{"issue":"12","key":"1054_CR40","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1007\/s13555-023-01054-3","volume":"13","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Langley RG, Gordon KB, Silverberg JI, Eyerich K, Sommer MOA, et al. Next generation PDE4 inhibitors that selectively target PDE4B\/D subtypes: a narrative review. Dermatol Ther. 2023;13(12):3031\u201342.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1054_CR41","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/jdv.18818","volume":"37","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, French LE, Warren RB, Strober B, Kj\u00f8ller K, Sommer MOA, et al. Pharmacology of orismilast, a potent and selective PDE4 inhibitor. J Eur Acad Dermatol Venereol JEADV. 2023;37(4):721\u20139.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"3","key":"1054_CR42","first-page":"574","volume":"47","author":"M Kaur","year":"2012","unstructured":"Kaur M, Bahia MS, Silakari O. Inhibitors of interleukin-2 inducible T-cell kinase as potential therapeutic candidates for the treatment of various inflammatory disease conditions. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2012;47(3):574\u201388.","journal-title":"Eur J Pharm Sci Off J Eur Fed Pharm Sci."},{"key":"1054_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pharmthera.2019.05.008","volume":"201","author":"S Solouki","year":"2019","unstructured":"Solouki S, August A, Huang W. Non-receptor tyrosine kinase signaling in autoimmunity and therapeutic implications. Pharmacol Ther. 2019;201:39\u201350.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"1054_CR44","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1021\/acsmedchemlett.1c00619","volume":"12","author":"AF Abdel-Magid","year":"2021","unstructured":"Abdel-Magid AF. Dual inhibition of IL-2-inducible T-cell kinase (ITK) and tropomyosin receptor kinase A (TRKA) as potential treatment for atopic dermatitis and other inflammatory and autoimmune diseases. ACS Med Chem Lett. 2021;12(12):1889\u201391.","journal-title":"ACS Med Chem Lett"},{"key":"1054_CR45","doi-asserted-by":"crossref","unstructured":"Abbas AK, Trotta E, R Simeonov D, Marson A, Bluestone JA. Revisiting IL-2: Biology and therapeutic prospects. Sci Immunol. 2018;3(25):eaat1482.","DOI":"10.1126\/sciimmunol.aat1482"},{"issue":"11","key":"1054_CR46","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrd.2018.148","volume":"17","author":"A Sharabi","year":"2018","unstructured":"Sharabi A, Tsokos MG, Ding Y, Malek TR, Klatzmann D, Tsokos GC. Regulatory T cells in the treatment of disease. Nat Rev Drug Discov. 2018;17(11):823\u201344.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"1054_CR47","first-page":"1092","volume":"159","author":"KE Nograles","year":"2008","unstructured":"Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Su\u00e1rez-Fari\u00f1as M, Cardinale I, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159(5):1092\u2013102.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1054_CR48","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","volume":"130","author":"JK Gittler","year":"2012","unstructured":"Gittler JK, Shemer A, Su\u00e1rez-Fari\u00f1as M, Fuentes-Duculan J, Gulewicz KJ, Wang CQF, et al. Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344\u201354.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"1054_CR49","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1038\/jid.2014.141","volume":"134","author":"N Dhingra","year":"2014","unstructured":"Dhingra N, Guttman-Yassky E. A possible role for IL-17A in establishing Th2 inflammation in murine models of atopic dermatitis. J Invest Dermatol. 2014;134(8):2071\u20134.","journal-title":"J Invest Dermatol"},{"key":"1054_CR50","unstructured":"Abbas A, Lichtman A, Pillai S, Henrickson S. Cellular and molecular immunology, 11th edn. Elsevier; 2025."},{"issue":"8","key":"1054_CR51","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/1744666X.2021.1940962","volume":"17","author":"C Dubin","year":"2021","unstructured":"Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol. 2021;17(8):835\u201352.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"1054_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41435-020-0095-7","volume":"21","author":"LEM Heeb","year":"2020","unstructured":"Heeb LEM, Egholm C, Boyman O. Evolution and function of interleukin-4 receptor signaling in adaptive immunity and neutrophils. Genes Immun. 2020;21(3):143\u20139.","journal-title":"Genes Immun"},{"issue":"7","key":"1054_CR53","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/all.14318","volume":"75","author":"CA Akdis","year":"2020","unstructured":"Akdis CA, Arkwright PD, Br\u00fcggen MC, Busse W, Gadina M, Guttman-Yassky E, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582\u2013605.","journal-title":"Allergy"},{"key":"1054_CR54","doi-asserted-by":"crossref","unstructured":"Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, DeBenedetto A, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009;124(3, Supplement 2):R7\u201312.","DOI":"10.1016\/j.jaci.2009.07.012"},{"issue":"8","key":"1054_CR55","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/1753425917732823","volume":"23","author":"L Bao","year":"2017","unstructured":"Bao L, Mohan GC, Alexander JB, Doo C, Shen K, Bao J, et al. A molecular mechanism for IL-4 suppression of loricrin transcription in epidermal keratinocytes: implication for atopic dermatitis pathogenesis. Innate Immun. 2017;23(8):641\u20137.","journal-title":"Innate Immun"},{"issue":"5","key":"1054_CR56","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/jid.2013.503","volume":"134","author":"M Omori-Miyake","year":"2014","unstructured":"Omori-Miyake M, Yamashita M, Tsunemi Y, Kawashima M, Yagi J. In vitro assessment of IL-4- or IL-13-mediated changes in the structural components of keratinocytes in mice and humans. J Invest Dermatol. 2014;134(5):1342\u201350.","journal-title":"J Invest Dermatol"},{"issue":"10356","key":"1054_CR57","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","volume":"400","author":"AS Paller","year":"2022","unstructured":"Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2022;400(10356):908\u201319.","journal-title":"Lancet Lond Engl."},{"issue":"10086","key":"1054_CR58","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2017;389(10086):2287\u2013303.","journal-title":"Lancet Lond Engl."},{"issue":"24","key":"1054_CR59","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"8","key":"1054_CR60","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/jamadermatol.2024.1536","volume":"160","author":"LA Beck","year":"2024","unstructured":"Beck LA, Bissonnette R, Deleuran M, Nakahara T, Galus R, Coleman A, et al. Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study. JAMA Dermatol. 2024;160(8):805\u201312.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1054_CR61","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jaci.2023.11.924","volume":"153","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Strober B, Feinstein B, Xu J, Guttman-Yassky E, Simpson EL, et al. Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4R\u03b1, in adults with moderate to severe atopic dermatitis: a phase 2 randomized trial (CBP-201-WW001). J Allergy Clin Immunol. 2024;153(4):1040\u20131049.e12.","journal-title":"J Allergy Clin Immunol"},{"key":"1054_CR62","doi-asserted-by":"crossref","unstructured":"Zhang J, Silverberg JI, Guo J, Yun J, Pan W, Wei Z, et al. Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized, phase II trial (SEASIDE CHINA): initial two-week dosing, followed by two-week or four-week dosing. Br J Dermatol. 2026;194(1):47\u201358.","DOI":"10.1093\/bjd\/ljaf347"},{"issue":"5","key":"1054_CR63","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/all.16368","volume":"80","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Zhang L, Wu L, Yang B, Wang J, Li Y, et al. Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial. Allergy. 2025;80(5):1348\u201357.","journal-title":"Allergy"},{"issue":"10","key":"1054_CR64","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s13555-023-01010-1","volume":"13","author":"CJ Wynne","year":"2023","unstructured":"Wynne CJ, Cole A, Lemech C, Wang G, Zhang Y, Chen B, et al. Safety, pharmacokinetics and preliminary efficacy of IL4-R\u03b1 monoclonal antibody AK120 in both healthy and atopic dermatitis subjects: a phase I, randomized, two-part, double-blind, placebo-controlled, dose-escalation, first-in-human clinical study. Dermatol Ther. 2023;13(10):2357\u201373.","journal-title":"Dermatol Ther"},{"key":"1054_CR65","doi-asserted-by":"publisher","DOI":"10.1177\/17103568251388478","author":"C Gu","year":"2025","unstructured":"Gu C, Zhang L, Li Y, Liang Y, Chen X, Ding Y, et al. MG-K10, a long-acting anti-IL-4 receptor alpha monoclonal antibody in adult patients with moderate-to-severe atopic dermatitis. Dermat Contact Atopic Occup Drug. 2025. https:\/\/doi.org\/10.1177\/17103568251388478.","journal-title":"Dermat Contact Atopic Occup Drug."},{"issue":"5","key":"1054_CR66","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40265-025-02151-7","volume":"85","author":"M Shirley","year":"2025","unstructured":"Shirley M. Stapokibart: first approval. Drugs. 2025;85(5):715\u201320.","journal-title":"Drugs"},{"issue":"1","key":"1054_CR67","doi-asserted-by":"publisher","first-page":"12411","DOI":"10.1038\/s41598-023-39311-2","volume":"13","author":"L Zhang","year":"2023","unstructured":"Zhang L, Ding Y, Wang Q, Pan W, Wei Z, Smith PA, et al. Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4R\u03b1, for the treatment of Th2 inflammatory diseases. Sci Rep. 2023;13(1):12411.","journal-title":"Sci Rep"},{"issue":"9","key":"1054_CR68","doi-asserted-by":"publisher","first-page":"110721","DOI":"10.1016\/j.isci.2024.110721","volume":"27","author":"W Liu","year":"2024","unstructured":"Liu W, Zhao Y, He Y, Yan X, Yu J, Song Q, et al. Stapokibart (CM310) targets IL-4R\u03b1 for the treatment of type 2 inflammation. iScience. 2024;27(9):110721.","journal-title":"iScience."},{"key":"1054_CR69","doi-asserted-by":"publisher","DOI":"10.1177\/17103568251361896","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Zhou C, Man X, Liu B, Geng S, Liang Y, et al. Efficacy and safety of extending dosing interval of stapokibart in patients with atopic dermatitis. Dermat Contact Atopic Occup Drug. 2025. https:\/\/doi.org\/10.1177\/17103568251361896.","journal-title":"Dermat Contact Atopic Occup Drug."},{"key":"1054_CR70","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf455","author":"M Zhao","year":"2025","unstructured":"Zhao M, Xu Z, Wu L, Wei Z, Yang B, Lin Z, et al. Safety and efficacy of stapokibart, an anti-IL-4R\u03b1 monoclonal antibody, in children aged 6\u201311 years with moderate-to-severe atopic dermatitis: an open-label, single-arm phase 1b\/2a trial. Br J Dermatol. 2025. https:\/\/doi.org\/10.1093\/bjd\/ljaf455.","journal-title":"Br J Dermatol"},{"key":"1054_CR71","unstructured":"Akeso Inc. Akeso reports phase 3 trials show positive results: gumokimab (IL-17) for ankylosing spondylitis and manfidokimab (IL-4R) for atopic dermatitis achieve primary endpoints. PR Newswire. Published September 2024. Accessed 20 Dec 2025."},{"key":"1054_CR72","unstructured":"ClinicalTrials.gov. A phase II study to evaluate the safety and efficacy of AK120 in subjects with moderate to severe atopic dermatitis. ClinicalTrials.gov Identifier: NCT06092762. Accessed 20 Dec 2025."},{"key":"1054_CR73","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety of AK120 in subjects with moderate to severe atopic dermatitis. ClinicalTrials.gov Identifier: NCT05048056. Accessed 20 Dec 2025."},{"key":"1054_CR74","unstructured":"ClinicalTrials.gov. A phase III randomized, double-blind, placebo-controlled study of AK120 in patients with moderate to severe atopic dermatitis. ClinicalTrials.gov Identifier: NCT06383468. Accessed 20 Dec 2025."},{"key":"1054_CR75","unstructured":"ClinicalTrials.gov. An open-label study to evaluate the efficacy and safety of AK120 in subjects with moderate to severe atopic dermatitis. ClinicalTrials.gov Identifier: NCT06700499. Accessed 20 Dec 2025)."},{"key":"1054_CR76","unstructured":"ClinicalTrials.gov. A phase III study evaluating the efficacy and safety of AK120 in adolescents with moderate to severe atopic dermatitis. ClinicalTrials.gov Identifier: NCT06767540. Accessed 20 Dec2025."},{"issue":"11","key":"1054_CR77","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1038\/s12276-022-00870-5","volume":"54","author":"S Ko","year":"2022","unstructured":"Ko S, Park S, Sohn MH, Jo M, Ko BJ, Na JH, et al. An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies. Exp Mol Med. 2022;54(11):1850\u201361.","journal-title":"Exp Mol Med"},{"key":"1054_CR78","unstructured":"ClinicalTrials.gov. Study of MG-K10 humanized monoclonal antibody injection in patients with atopic dermatitis (AD). ClinicalTrials.gov Identifier: NCT06026891. Accessed 20 Dec 2025."},{"key":"1054_CR79","unstructured":"ClinicalTrials.gov. IB\/IIa study of MG-K10 humanized monoclonal antibody injection in adolescent participants with moderate-to-severe atopic dermatitis (AD). ClinicalTrials.gov Identifier: NCT06765005. Accessed 20 Dec 2025."},{"issue":"1","key":"1054_CR80","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cyto.2015.05.010","volume":"75","author":"J Zhu","year":"2015","unstructured":"Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine. 2015;75(1):14\u201324.","journal-title":"Cytokine"},{"issue":"1","key":"1054_CR81","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/ni1544","volume":"9","author":"TR Ramalingam","year":"2008","unstructured":"Ramalingam TR, Pesce JT, Sheikh F, Cheever AW, Mentink-Kane MM, Wilson MS, et al. Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor \u03b11 chain. Nat Immunol. 2008;9(1):25\u201333.","journal-title":"Nat Immunol"},{"issue":"12","key":"1054_CR82","first-page":"7716","volume":"174","author":"SC Fish","year":"2005","unstructured":"Fish SC, Donaldson DD, Goldman SJ, Williams CMM, Kasaian MT. IgE generation and mast cell effector function in mice deficient in IL-4 and IL-13. J Immunol Baltim Md 1950. 2005;174(12):7716\u201324.","journal-title":"J Immunol Baltim Md 1950."},{"issue":"7","key":"1054_CR83","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","volume":"139","author":"LC Tsoi","year":"2019","unstructured":"Tsoi LC, Rodriguez E, Degenhardt F, Baurecht H, Wehkamp U, Volks N, et al. Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol. 2019;139(7):1480\u20139.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"1054_CR84","doi-asserted-by":"publisher","first-page":"300060524128683","DOI":"10.1177\/03000605241286832","volume":"52","author":"C Teixeira","year":"2024","unstructured":"Teixeira C, Yilmaz O, Bernardo D, Torres T. IL-13 inhibition in the treatment of atopic dermatitis - new and emerging biologic agents. J Int Med Res. 2024;52(11):3000605241286832. https:\/\/doi.org\/10.1177\/03000605241286832.","journal-title":"J Int Med Res"},{"issue":"3","key":"1054_CR85","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jaad.2023.10.026","volume":"90","author":"KA Veverka","year":"2024","unstructured":"Veverka KA, Thng STG, Silverberg JI, Armstrong AW, Menezes J, Kaoukhov A, et al. Safety and efficacy of eblasakimab, an interleukin 13 receptor \u03b11 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study. J Am Acad Dermatol. 2024;90(3):504\u201311.","journal-title":"J Am Acad Dermatol"},{"key":"1054_CR86","doi-asserted-by":"crossref","unstructured":"Guttman-Yassky E, Blauvelt A, Gooderham M, et al. APG777, a novel, half-life extended anti-IL-13 antibody, demonstrates safety and efficacy in moderate-to-severe atopic dermatitis: 16-week results from the phase 2 APEX study. Presented at: EADV Congress 2025; September 17\u201320, 2025; Paris, France. Late-breaking abstract LBA-149. Available from:\u00a0https:\/\/eadv.org\/wp-content\/uploads\/scientific-abstracts\/EADV-congress-2025\/EADV-Congress-2025-Paris-Late-breaking-abstracts.pdf. Accessed 25 May 2026.","DOI":"10.1016\/j.jid.2025.09.173"},{"issue":"4","key":"1054_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2025.100545","volume":"4","author":"E Zhu","year":"2025","unstructured":"Zhu E, Prentice H, Oh J, Shaheen H, Gandhi NA, Wickman G, et al. In vitro potency and pharmacokinetics of APG777, a novel anti-IL-13 mAb. J Allergy Clin Immunol Glob. 2025;4(4):100545. https:\/\/doi.org\/10.1016\/j.jacig.2025.100545.","journal-title":"J Allergy Clin Immunol Glob."},{"issue":"36","key":"1054_CR88","doi-asserted-by":"publisher","first-page":"24289","DOI":"10.1074\/jbc.M109.007286","volume":"284","author":"T Ito","year":"2009","unstructured":"Ito T, Suzuki S, Kanaji S, Shiraishi H, Ohta S, Arima K, et al. Distinct structural requirements for interleukin-4 (IL-4) and IL-13 binding to the shared IL-13 receptor facilitate cellular tuning of cytokine responsiveness. J Biol Chem. 2009;284(36):24289\u201396.","journal-title":"J Biol Chem"},{"issue":"6","key":"1054_CR89","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/10915818251355584","volume":"44","author":"D Rubio","year":"2025","unstructured":"Rubio D, Zhu E, Thurston A, Funk KA, York KA, Dambkowski CL, et al. Preclinical safety of APG777, a novel extended half-life anti-interleukin-13 monoclonal antibody, in Cynomolgus Monkeys. Int J Toxicol. 2025;44(6):443\u201350.","journal-title":"Int J Toxicol"},{"issue":"2","key":"1054_CR90","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nbt.1601","volume":"28","author":"J Zalevsky","year":"2010","unstructured":"Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IWL, Sproule TJ, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28(2):157\u20139.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"1054_CR91","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70456","volume":"18","author":"XQ Lim","year":"2025","unstructured":"Lim XQ, Winter E, Nograles K, Xu J, Zhang ZQ, Thankamony S, et al. A first-in-human, single- and multiple-dose study of APG777, a half-life-extended anti-IL-13 monoclonal antibody, in healthy volunteers. Clin Transl Sci. 2025;18(12):e70456.","journal-title":"Clin Transl Sci"},{"key":"1054_CR92","unstructured":"A study evaluating APG777 in atopic dermatitis (APG777-201) (NCT06395948). ClinicalTrials.gov; Phase 2, randomized, double-blind, placebo-controlled trial evaluating safety and efficacy of APG777 in adults with moderate-to-severe atopic dermatitis. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06395948. Accessed 24 Dec 2025."},{"key":"1054_CR93","unstructured":"Apogee therapeutics announces positive 16-week data from phase 2 APEX Clinical Trial of APG777, its potentially best-in-class anti-IL-13 antibody in moderate-to-severe atopic dermatitis. Apogee Therapeutics, Inc. Press release. July 7, 2025. Available at: https:\/\/investors.apogeetherapeutics.com\/node\/8286\/pdf. Accessed 23 Dec 2025."},{"key":"1054_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109677","volume":"253","author":"F Cevikbas","year":"2023","unstructured":"Cevikbas F, Ward A, Firth C, Veverka K. Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers. Clin Immunol Orlando Fla. 2023;253:109677. https:\/\/doi.org\/10.1016\/j.clim.2023.109677.","journal-title":"Clin Immunol Orlando Fla."},{"issue":"6","key":"1054_CR95","first-page":"821","volume":"38","author":"F Cevikbas","year":"2024","unstructured":"Cevikbas F, Ward A, Veverka KA. Eblasakimab, an anti-IL-13R\u03b11 antibody, reduces atopy-associated serum biomarkers in moderate-to-severe atopic dermatitis. BioDrugs Clin Immunother Biopharm Gene Ther. 2024;38(6):821\u201330.","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther."},{"key":"1054_CR96","unstructured":"ASLAN Pharmaceuticals. ASLAN Pharmaceuticals announces positive interim results from phase 2 study of eblasakimab in dupilumab-experienced atopic dermatitis patients. GlobeNewswire. April 22, 2024. Accessed 24 Dec2025."},{"issue":"2","key":"1054_CR97","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1111\/j.1468-3083.2012.04587.x","volume":"27","author":"T Ilves","year":"2013","unstructured":"Ilves T, Harvima IT. OX40 ligand and OX40 are increased in atopic dermatitis lesions but do not correlate with clinical severity. J Eur Acad Dermatol Venereol JEADV. 2013;27(2):e197-205.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"5","key":"1054_CR98","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jaci.2007.03.006","volume":"119","author":"E Guttman-Yassky","year":"2007","unstructured":"Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Whynot J, Novitskaya I, Cardinale I, et al. Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol. 2007;119(5):1210\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1054_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primer. 2018;4(1):1.","journal-title":"Nat Rev Dis Primer"},{"key":"1054_CR100","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1600-065X.1996.tb00921.x","volume":"153","author":"IS Grewal","year":"1996","unstructured":"Grewal IS, Flavell RA. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev. 1996;153:85\u2013106.","journal-title":"Immunol Rev"},{"issue":"12","key":"1054_CR101","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L. B7\u2013H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365\u20139.","journal-title":"Nat Med"},{"key":"1054_CR102","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3389\/fphar.2018.00642","volume":"9","author":"Y Tai","year":"2018","unstructured":"Tai Y, Wang Q, Korner H, Zhang L, Wei W. Molecular mechanisms of T cells activation by dendritic cells in autoimmune diseases. Front Pharmacol. 2018;9:642.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1054_CR103","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40257-023-00838-9","volume":"25","author":"M Croft","year":"2024","unstructured":"Croft M, Esfandiari E, Chong C, Hsu H, Kabashima K, Kricorian G, et al. OX40 in the pathogenesis of atopic dermatitis\u2014a new therapeutic target. Am J Clin Dermatol. 2024;25(3):447\u201361.","journal-title":"Am J Clin Dermatol"},{"key":"1054_CR104","doi-asserted-by":"crossref","unstructured":"Nicol\u00e0s LS de S, Czarnowicki T, Akdis M, Pujol RM, Lozano-Ojalvo D, Leung DYM, et al. CLA+ memory T cells in atopic dermatitis. Allergy. 2024;79(1):15\u201325.","DOI":"10.1111\/all.15816"},{"issue":"3","key":"1054_CR105","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.celrep.2018.06.052","volume":"24","author":"X Zhang","year":"2018","unstructured":"Zhang X, Xiao X, Lan P, Li J, Dou Y, Chen W, et al. OX40 costimulation inhibits Foxp3 expression and treg induction via BATF3-dependent and independent mechanisms. Cell Rep. 2018;24(3):607\u201318.","journal-title":"Cell Rep"},{"issue":"7","key":"1054_CR106","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1182\/blood-2007-01-070748","volume":"110","author":"MD Vu","year":"2007","unstructured":"Vu MD, Xiao X, Gao W, Degauque N, Chen M, Kroemer A, et al. OX40 costimulation turns off Foxp3+ Tregs. Blood. 2007;110(7):2501\u201310.","journal-title":"Blood"},{"key":"1054_CR107","doi-asserted-by":"crossref","unstructured":"Elsner JS, Carlsson M, Stougaard JK, Nygaard U, Buchner M, F\u00f6lster-Holst R, et al. The OX40 axis is associated with both systemic and local involvement in atopic dermatitis. Acta Derm Venereol. 2020;100(6):adv00099.","DOI":"10.2340\/00015555-3452"},{"issue":"25","key":"1054_CR108","first-page":"01865","volume":"S0140\u20136736","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Kabashima K, Worm M, Luna PC, Hong HCH, Chovatiya R, et al. Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials. Lancet Lond Engl. 2025;S0140\u20136736(25):01865\u201373.","journal-title":"Lancet Lond Engl."},{"key":"1054_CR109","unstructured":"A study to evaluate the safety, tolerability, pharmacokinetics, efficacy, and pharmacodynamics of IMG-007 in participants with atopic dermatitis (AD) (NCT05984784). ClinicalTrials.gov. Updated November 1, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05984784. Accessed 30 Dec 2025."},{"issue":"1","key":"1054_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2023.100195","volume":"3","author":"B Rewerska","year":"2024","unstructured":"Rewerska B, Sher LD, Alpizar S, Pauser S, Pulka G, Mozaffarian N, et al. Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Glob. 2024;3(1):100195.","journal-title":"J Allergy Clin Immunol Glob."},{"issue":"4","key":"1054_CR111","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jaci.2024.10.031","volume":"155","author":"S Weidinger","year":"2025","unstructured":"Weidinger S, Blauvelt A, Papp KA, et al. Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2025;155(4):1264\u201375.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1054_CR112","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/1750743X.2025.2464528","volume":"17","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Simpson E, Bissonnette R, Eichenfield LF, Kabashima K, Luna PC, et al. ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis. Immunotherapy. 2025;17(2):83\u201394.","journal-title":"Immunotherapy"},{"issue":"10372","key":"1054_CR113","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","volume":"401","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Simpson EL, Reich K, Kabashima K, Igawa K, Suzuki T, et al. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet Lond Engl. 2023;401(10372):204\u201314.","journal-title":"Lancet Lond Engl."},{"key":"1054_CR114","unstructured":"Kyowa Kirin Co., Ltd. Kyowa Kirin announces discontinuation of rocatinlimab clinical trials. Tokyo: Kyowa Kirin; 2026 Mar 3. Available from: https:\/\/www.kyowakirin.com\/media_center\/news_releases\/2026\/e20260303_01.html. Accessed 2026 May 25."},{"key":"1054_CR115","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae266.076","author":"Y Shen","year":"2024","unstructured":"Shen Y, Lin Z, Guo C, Nair A, Lu Y, Silverberg JI. 702 - IMG-007, a nondepleting OX40 monoclonal antibody with an extended half-life, improves skin lesions in adults with moderate-to-severe atopic dermatitis: interim results from a phase 2a trial. Br J Dermatol. 2024. https:\/\/doi.org\/10.1093\/bjd\/ljae266.076.","journal-title":"Br J Dermatol"},{"key":"1054_CR116","unstructured":"Inmagene Biopharmaceuticals. Inmagene\u2019s OX40 mAb, with an extended half-life and silenced ADCC, enters POC study in atopic dermatitis. PR Newswire. August 15, 2023. https:\/\/www.prnewswire.com\/news-releases\/inmagenes-ox40-mab-with-an-extended-half-life-and-silenced-adcc-enters-poc-study-in-atopic-dermatitis-301901200.html. Accessed 30 Dec 2025."},{"key":"1054_CR117","unstructured":"Inmagene Biopharmaceuticals. Inmagene reports positive topline results of IMG-007, a nondepleting anti-OX40 monoclonal antibody with an extended half-life for the treatment of atopic dermatitis. BioSpace. January 9, 2025. https:\/\/www.biospace.com\/press-releases\/inmagene-reports-positive-topline-results-of-img-007-a-nondepleting-anti-ox40-monoclonal-antibody-with-an-extended-half-life-for-the-treatment-of-atopic-dermatitis. Accessed 30 Dec 2025."},{"key":"1054_CR118","unstructured":"Smith T. New phase 2a findings released on IMG-007 treatment of atopic dermatitis. HCP Live [Internet]. 2025 Jan 9 [cited 2025 Dec 30]. Available from: https:\/\/www.hcplive.com\/view\/new-phase-2a-findings-released-img-007-treatment-atopic-dermatitis."},{"key":"1054_CR119","unstructured":"ClinicalTrials.gov. A study to evaluate the safety and efficacy of IMG-007 in adults with moderate to severe atopic dermatitis. ClinicalTrials.gov identifier: NCT07037901. https:\/\/clinicaltrials.gov\/study\/NCT07037901. Accessed 30 Dec 2025."},{"issue":"5","key":"1054_CR120","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/cpt.2539","volume":"111","author":"M Saghari","year":"2022","unstructured":"Saghari M, Gal P, Gilbert S, Yateman M, Porter-Brown B, Brennan N, et al. OX40L inhibition suppresses KLH-driven immune responses in healthy volunteers: a randomized controlled trial demonstrating proof-of-pharmacology for KY1005. Clin Pharmacol Ther. 2022;111(5):1121\u201332.","journal-title":"Clin Pharmacol Ther"},{"key":"1054_CR121","doi-asserted-by":"crossref","unstructured":"Krueger JG, Kim BS, Weidinger S, Kataoka Y, O\u2019Malley JT, Yen K, et al. In vitro evidence demonstrating the nondepleting mechanism of action of amlitelimab, an OX40 ligand monoclonal antibody. Acta Derm Venereol. 2025;105:adv43608.","DOI":"10.2340\/actadv.v105.43608"},{"key":"1054_CR122","unstructured":"Sanofi. Sanofi announces positive results from the global phase 3 COAST-1 study of amlitelimab in adults and adolescents with atopic dermatitis. Press release. September 4, 2025. https:\/\/www.sanofi.com\/assets\/dotcom\/pressreleases\/2025\/2025-09-04-05-00-00-3144170-en.pdf. Accessed 30 Dec 2025."},{"key":"1054_CR123","unstructured":"Sanofi. OCEANA Clinical Program Investigating amlitelimab in atopic dermatitis. Sanofi. Available at: https:\/\/www.sanofi.com\/en\/our-science\/clinical-trials-and-results\/oceana-clinical-program-investigating-amlitelimab-in-atopic-dermatitis. Accessed 30 Dec 2025."},{"issue":"5","key":"1054_CR124","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1084\/jem.20041982","volume":"201","author":"R Setoguchi","year":"2005","unstructured":"Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005;201(5):723\u201335.","journal-title":"J Exp Med"},{"key":"1054_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(08)60386-7","volume":"70","author":"BH Nelson","year":"1998","unstructured":"Nelson BH, Willerford DM. Biology of the interleukin-2 receptor. Adv Immunol. 1998;70:1\u201381.","journal-title":"Adv Immunol"},{"issue":"3","key":"1054_CR126","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180\u201390.","journal-title":"Nat Rev Immunol"},{"key":"1054_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100103","volume":"4","author":"N Dixit","year":"2021","unstructured":"Dixit N, Fanton C, Langowski JL, Kirksey Y, Kirk P, Chang T, et al. NKTR-358: a novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. J Transl Autoimmun. 2021;4:100103.","journal-title":"J Transl Autoimmun."},{"key":"1054_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2022.100152","volume":"5","author":"C Fanton","year":"2022","unstructured":"Fanton C, Furie R, Chindalore V, Levin R, Diab I, Dixit N, et al. Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus. J Transl Autoimmun. 2022;5:100152.","journal-title":"J Transl Autoimmun."},{"issue":"1","key":"1054_CR129","doi-asserted-by":"publisher","first-page":"9230","DOI":"10.1038\/s41467-024-53384-1","volume":"15","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Rosmarin D, Chovatiya R, Bieber T, Schleicher S, Beck L, et al. The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials. Nat Commun. 2024;15(1):9230.","journal-title":"Nat Commun"},{"key":"1054_CR130","unstructured":"Nektar Therapeutics. New data from REZOLVE-AD study of rezpegaldesleukin (REZPEG). Press release. Nov 8, 2025. Available at: https:\/\/ir.nektar.com\/node\/22326\/pdf. Accessed 2 Jan 2026."},{"key":"1054_CR131","unstructured":"Nektar Therapeutics.\u00a0New REZOLVE-AD maintenance data in atopic dermatitis demonstrate rezpegaldesleukin resulted in durable and new responses across key disease measurements with both monthly and quarterly dosing. Nektar Therapeutics; Feb 10, 2026. Available at:\u00a0https:\/\/ir.nektar.com\/news-releases\/news-release-details\/new-rezolve-ad-maintenance-data-atopic-dermatitis-demonstrate. Accessed 6 Mar 2026."},{"key":"1054_CR132","unstructured":"ClinicalTrials.gov. A phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of SIM0278 in subjects with moderate to severe atopic dermatitis. ClinicalTrials.gov Identifier: NCT07175233. Updated October 8, 2025. Available at: https:\/\/clinicaltrials.gov\/study\/NCT07175233. Accessed 2 Jan 2026."},{"issue":"3","key":"1054_CR133","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/bjd.16934","volume":"180","author":"T Tsakok","year":"2019","unstructured":"Tsakok T, Woolf R, Smith CH, Weidinger S, Flohr C. Atopic dermatitis: the skin barrier and beyond. Br J Dermatol. 2019;180(3):464\u201374.","journal-title":"Br J Dermatol"},{"key":"1054_CR134","unstructured":"ClinicalTrials.gov. A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of ATI-045 in patients with moderate-to-severe atopic dermatitis (ATI-045-AD-201). ClinicalTrials.gov Identifier: NCT07011706. Last updated October 30, 2025. Available at: https:\/\/clinicaltrials.gov\/study\/NCT07011706. Accessed 2 Jan 2026."},{"key":"1054_CR135","unstructured":"ClinicalTrials.gov. A pilot phase 2A study to examine the preliminary efficacy, safety, and pharmacokinetics of TAVO101 in patients with moderate to severe atopic dermatitis. ClinicalTrials.gov Identifier: NCT06176040. Last updated November 18, 2024. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06176040. Accessed 2 Jan 2026."},{"key":"1054_CR136","unstructured":"ClinicalTrials.gov. A study to investigate the efficacy and safety of SHR-1905 injection in patients with moderate-to-severe atopic dermatitis. ClinicalTrials.gov Identifier: NCT07211542. Last updated December 1, 2025. Available at: https:\/\/clinicaltrials.gov\/study\/NCT07211542. Accessed 2 Jan 2026."},{"key":"1054_CR137","unstructured":"ClinicalTrials.gov. A phase 1 study of single and multiple intravenous doses of SM17 in healthy subjects.ClinicalTrials.gov Identifier: NCT05332834. Last updated March 12, 2025. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05332834. Accessed 2 Jan 2026."},{"key":"1054_CR138","unstructured":"ClinicalTrials.gov. A multicenter, randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the efficacy and safety of XKH001 injection in patients with moderate-to-severe atopic dermatitis. ClinicalTrials.gov Identifier: NCT07054736. Last updated November 17, 2025. Available at: https:\/\/clinicaltrials.gov\/study\/NCT07054736. Accessed 2 Jan 2026."},{"issue":"4","key":"1054_CR139","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","volume":"80","author":"EL Simpson","year":"2019","unstructured":"Simpson EL, Parnes JR, She D, Crouch S, Rees W, Mo M, et al. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial. J Am Acad Dermatol. 2019;80(4):1013\u201321.","journal-title":"J Am Acad Dermatol"},{"key":"1054_CR140","unstructured":"Aclaris Therapeutics, Inc. Form 8-K: Exhibit 99.1 \u2013 Corporate Presentation. Filed January 13, 2025. U.S. Securities and Exchange Commission. Available at: https:\/\/www.sec.gov\/Archives\/edgar\/data\/1557746\/000155837025000148\/acrs-20250113xex99d1.htm. Accessed 19 Dec 2025."},{"key":"1054_CR141","doi-asserted-by":"publisher","unstructured":"Parish J, Appel J, Silverberg J, Zhang C, Teng S, Zhang J, et al. Clinical efficacy, safety, and pharmacokinetic profile of bosakitug (BSI-045B), an anti-thymic stromal lymphopoietin (TSLP) mAb in a phase 2 study of moderate and severe atopic dermatitis subjects. Br J Dermatol. 2024;191(Supplement_2). https:\/\/doi.org\/10.1093\/bjd\/ljae266.090","DOI":"10.1093\/bjd\/ljae266.090"},{"key":"1054_CR142","unstructured":"Aclaris Therapeutics. Aclaris Therapeutics announces positive top-line results from open-label Phase 2a trial of ATI-2138, a potent and selective investigational inhibitor of ITK and JAK3, achieving primary and key secondary endpoints. Press release. July 29, 2025. Available at: Aclaris Therapeutics Investor Relations website. Accessed December 12, 2025."},{"issue":"4","key":"1054_CR143","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/bjd.21631","volume":"187","author":"V Laquer","year":"2022","unstructured":"Laquer V, Parra V, Lacour JP, Takahashi H, Knorr J, Okragly AJ, et al. Interleukin-33 antibody failed to demonstrate benefit in a phase II, double-blind, randomized, placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis. Br J Dermatol. 2022;187(4):599\u2013602.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1054_CR144","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13874","volume":"17","author":"MP Kosloski","year":"2024","unstructured":"Kosloski MP, Guttman-Yassky E, Cork MJ, Worm M, Nahm DH, Zhu X, et al. Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: results from two terminated phase II trials. Clin Transl Sci. 2024;17(8):e13874.","journal-title":"Clin Transl Sci"},{"issue":"6","key":"1054_CR145","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.jaci.2022.08.015","volume":"150","author":"M Maurer","year":"2022","unstructured":"Maurer M, Cheung DS, Theess W, Yang X, Dolton M, Guttman A, et al. Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis. J Allergy Clin Immunol. 2022;150(6):1517\u201324.","journal-title":"J Allergy Clin Immunol"},{"key":"1054_CR146","doi-asserted-by":"crossref","unstructured":"Chen YL, Gutowska-Owsiak D, Hardman CS, Westmoreland M, MacKenzie T, Cifuentes L, et al. Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. Sci Transl Med. 2019;11(515):eaax2945.","DOI":"10.1126\/scitranslmed.aax2945"},{"issue":"1","key":"1054_CR147","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41584-023-01053-w","volume":"20","author":"E Landy","year":"2024","unstructured":"Landy E, Carol H, Ring A, Canna S. Biological and clinical roles of IL-18 in inflammatory diseases. Nat Rev Rheumatol. 2024;20(1):33\u201347.","journal-title":"Nat Rev Rheumatol"},{"issue":"24","key":"1054_CR148","doi-asserted-by":"publisher","first-page":"13962","DOI":"10.1073\/pnas.96.24.13962","volume":"96","author":"T Yoshimoto","year":"1999","unstructured":"Yoshimoto T, Tsutsui H, Tominaga K, Hoshino K, Okamura H, Akira S, et al. IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci USA. 1999;96(24):13962\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1054_CR149","doi-asserted-by":"crossref","unstructured":"Rodriguez-Gal\u00e1n MC, Bream JH, Farr A, Young HA. Synergistic effect of IL-2, IL-12, and IL-18 on thymocyte apoptosis and Th1\/Th2 cytokine expression. J Immunol Baltim Md 1950. 2005;174(5):2796\u2013804.","DOI":"10.4049\/jimmunol.174.5.2796"},{"issue":"2","key":"1054_CR150","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jaci.2024.10.027","volume":"155","author":"S Sch\u00e4rli","year":"2025","unstructured":"Sch\u00e4rli S, Luther F, Di Domizio J, Hillig C, Radonjic-Hoesli S, Thormann K, et al. IL-9 sensitizes human TH2 cells to proinflammatory IL-18 signals in atopic dermatitis. J Allergy Clin Immunol. 2025;155(2):491-504.e9.","journal-title":"J Allergy Clin Immunol"},{"key":"1054_CR151","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.biopha.2017.05.126","volume":"92","author":"S Patel","year":"2017","unstructured":"Patel S. Inflammasomes, the cardinal pathology mediators are activated by pathogens, allergens and mutagens: a critical review with focus on NLRP3. Biomed Pharmacother Biomedecine Pharmacother. 2017;92:819\u201325.","journal-title":"Biomed Pharmacother Biomedecine Pharmacother."},{"key":"1054_CR152","doi-asserted-by":"crossref","unstructured":"Vaher H, Kingo K, Kolberg P, Pook M, Raam L, Laanesoo A, et al. Skin colonization with S.\u00a0aureus can lead to increased NLRP1 inflammasome activation in\u00a0patients with atopic dermatitis. J Invest Dermatol. 2023;143(7):1268\u20131278.e8.","DOI":"10.1016\/j.jid.2023.01.013"},{"issue":"3","key":"1054_CR153","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1073\/pnas.97.3.1190","volume":"97","author":"SH Kim","year":"2000","unstructured":"Kim SH, Eisenstein M, Reznikov L, Fantuzzi G, Novick D, Rubinstein M, et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci USA. 2000;97(3):1190\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1054_CR154","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/ni.3103","volume":"16","author":"CA Nold-Petry","year":"2015","unstructured":"Nold-Petry CA, Lo CY, Rudloff I, Elgass KD, Li S, Gantier MP, et al. IL-37 requires the receptors IL-18R\u03b1 and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol. 2015;16(4):354\u201365.","journal-title":"Nat Immunol"},{"issue":"7","key":"1054_CR155","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1111\/all.14769","volume":"76","author":"T Hou","year":"2021","unstructured":"Hou T, Tsang MSM, Chu IMT, Kan LLY, Hon KL, Leung TF, et al. Skewed inflammation is associated with aberrant interleukin-37 signaling pathway in atopic dermatitis. Allergy. 2021;76(7):2102\u201314.","journal-title":"Allergy"},{"key":"1054_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2023.156413","volume":"172","author":"YS Jang","year":"2023","unstructured":"Jang YS, Lee K, Park M, Joo Park J, Choi GM, Kim C, et al. Albumin-binding recombinant human IL-18BP ameliorates macrophage activation syndrome and atopic dermatitis via direct IL-18 inactivation. Cytokine. 2023;172:156413.","journal-title":"Cytokine"},{"issue":"10","key":"1054_CR157","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41590-018-0201-4","volume":"19","author":"RR Ricardo-Gonzalez","year":"2018","unstructured":"Ricardo-Gonzalez RR, Van Dyken SJ, Schneider C, Lee J, Nussbaum JC, Liang HE, et al. Tissue signals imprint ILC2 identity with anticipatory function. Nat Immunol. 2018;19(10):1093\u20139.","journal-title":"Nat Immunol"},{"issue":"2","key":"1054_CR158","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jaci.2021.07.025","volume":"149","author":"N Alkon","year":"2022","unstructured":"Alkon N, Bauer WM, Krausgruber T, Goh I, Griss J, Nguyen V, et al. Single-cell analysis reveals innate lymphoid cell lineage infidelity in atopic dermatitis. J Allergy Clin Immunol. 2022;149(2):624\u201339.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"1054_CR159","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/j.1365-2230.2011.04113.x","volume":"36","author":"M Trzeciak","year":"2011","unstructured":"Trzeciak M, Gle\u0144 J, Bandurski T, Soko\u0142owska-Wojdy\u0142o M, Wilkowska A, Roszkiewicz J. Relationship between serum levels of interleukin-18, IgE and disease severity in patients with atopic dermatitis. Clin Exp Dermatol. 2011;36(7):728\u201332.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"1054_CR160","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/all.15153","volume":"77","author":"AM Andersson","year":"2022","unstructured":"Andersson AM, S\u00f8lberg J, Koch A, Skov L, Jakasa I, Kezic S, et al. Assessment of biomarkers in pediatric atopic dermatitis by tape strips and skin biopsies. Allergy. 2022;77(5):1499\u2013509.","journal-title":"Allergy"},{"issue":"913","key":"1054_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2024.148397","volume":"30","author":"Y Huang","year":"2024","unstructured":"Huang Y, Zhou W, Liu S, Zeng D, Zhou W. Association between polymorphisms and atopic dermatitis susceptibility: a systematic review and meta-analysis. Gene. 2024;30(913):148397.","journal-title":"Gene"},{"issue":"11","key":"1054_CR162","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1016\/j.jid.2021.03.027","volume":"141","author":"MK Sobczyk","year":"2021","unstructured":"Sobczyk MK, Richardson TG, Zuber V, Min JL, Gaunt TR, Paternoster L, et al. Triangulating molecular evidence to prioritize candidate causal genes at established atopic dermatitis loci. J Invest Dermatol. 2021;141(11):2620\u20139.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"1054_CR163","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/ng.3424","volume":"47","author":"L Paternoster","year":"2015","unstructured":"Paternoster L, Standl M, Waage J, Baurecht H, Hotze M, Strachan DP, et al. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet. 2015;47(12):1449\u201356.","journal-title":"Nat Genet"},{"key":"1054_CR164","unstructured":"Evommune Inc.\u00a0Evommune announces positive top-line data from phase 2a proof-of-concept trial of EVO301 in moderate-to-severe atopic dermatitis. Feb 10, 2026. Available at:\u00a0https:\/\/ir.evommune.com\/news-events\/press-releases\/detail\/119\/evommune-announces-positive-top-line-data-from-phase-2a-proof-of-concept-trial-of-evo301-in-moderate-to-severe-atopic-dermatitis. Accessed 6 Mar 2026."},{"key":"1054_CR165","doi-asserted-by":"crossref","unstructured":"Ellis J, Fortunato L, Wajdner H, Del Duca E, Barnard J, Betts JC, et al. Clinical and molecular effect of the anti-IL-18 antibody aletekitug in adults with atopic dermatitis. Allergy. 2026;81(2):539\u2013551.","DOI":"10.1111\/all.70172"},{"key":"1054_CR166","unstructured":"Apollo Therapeutics Ltd. A phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe atopic dermatitis (NCT06436183). ClinicalTrials.gov identifier NCT06436183. Last updated 2025. https:\/\/clinicaltrials.gov\/study\/NCT06436183. Accessed 27 Dec 2025."},{"key":"1054_CR167","unstructured":"Apollo Therapeutics. Apollo therapeutics\u2019 anti-IL-18 antibody camoteskimab met the primary endpoint in a double-blind, randomized, placebo-controlled phase 2a clinical trial in atopic dermatitis. September 16, 2025. Apollo Therapeutics. https:\/\/www.apollotx.com\/news\/apollo-therapeutics-anti-il-18-antibody-camoteskimab-met-the-primary-endpoint\/. Accessed 27 Dec 2025."},{"key":"1054_CR168","unstructured":"GlaxoSmithKline. A dose finding study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of GSK1070806 in adult participants with moderate to severe atopic dermatitis (NCT05999799). ClinicalTrials.gov identifier NCT05999799. Updated 2025. https:\/\/clinicaltrials.gov\/study\/NCT05999799. Accessed 27 Dec 2025."},{"key":"1054_CR169","unstructured":"GlaxoSmithKline. Long-term study (AtDvance) to evaluate GSK1070806 in participants with moderate to severe atopic dermatitis (NCT06447506). ClinicalTrials.gov identifier NCT06447506. Updated 2025. https:\/\/clinicaltrials.gov\/study\/NCT06447506. Accessed 27 Dec 2025."},{"issue":"11","key":"1054_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.09.132","volume":"145","author":"J Harden","year":"2025","unstructured":"Harden J, Whitener R, Jacobson A, Pavel A, Park J, Chi S, et al. EVO301: an IL18BP-SAFA biologic demonstrates prolonged residence in inflamed skin and efficacy in a preclinical atopic dermatitis model. J Investig Dermatol. 2025;145(11):e50.","journal-title":"J Investig Dermatol"},{"issue":"12","key":"1054_CR171","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nri3766","volume":"14","author":"S Rutz","year":"2014","unstructured":"Rutz S, Wang X, Ouyang W. The IL-20 subfamily of cytokines\u2013from host defence to tissue homeostasis. Nat Rev Immunol. 2014;14(12):783\u201395.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"1054_CR172","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nm1710","volume":"14","author":"SJ Aujla","year":"2008","unstructured":"Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med. 2008;14(3):275\u201381.","journal-title":"Nat Med"},{"issue":"6","key":"1054_CR173","first-page":"3695","volume":"174","author":"K Boniface","year":"2005","unstructured":"Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol Baltim Md 1950. 2005;174(6):3695\u2013702.","journal-title":"J Immunol Baltim Md 1950."},{"issue":"5","key":"1054_CR174","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/eji.200535503","volume":"36","author":"K Wolk","year":"2006","unstructured":"Wolk K, Witte E, Wallace E, D\u00f6cke WD, Kunz S, Asadullah K, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006;36(5):1309\u201323.","journal-title":"Eur J Immunol"},{"issue":"1","key":"1054_CR175","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrd4176","volume":"13","author":"R Sabat","year":"2014","unstructured":"Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov. 2014;13(1):21\u201338.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1054_CR176","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","volume":"132","author":"M Su\u00e1rez-Fari\u00f1as","year":"2013","unstructured":"Su\u00e1rez-Fari\u00f1as M, Dhingra N, Gittler J, Shemer A, Cardinale I, de Guzman SC, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013;132(2):361\u201370.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1054_CR177","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","volume":"78","author":"E Guttman-Yassky","year":"2018","unstructured":"Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial. J Am Acad Dermatol. 2018;78(5):872-881.e6.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1054_CR178","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","volume":"143","author":"PM Brunner","year":"2019","unstructured":"Brunner PM, Pavel AB, Khattri S, Leonard A, Malik K, Rose S, et al. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. J Allergy Clin Immunol. 2019;143(1):142\u201354.","journal-title":"J Allergy Clin Immunol"},{"issue":"31","key":"1054_CR179","doi-asserted-by":"publisher","first-page":"12704","DOI":"10.1073\/pnas.1117551109","volume":"109","author":"NJ Logsdon","year":"2012","unstructured":"Logsdon NJ, Deshpande A, Harris BD, Rajashankar KR, Walter MR. Structural basis for receptor sharing and activation by interleukin-20 receptor-2 (IL-20R2) binding cytokines. Proc Natl Acad Sci USA. 2012;109(31):12704\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"25","key":"1054_CR180","first-page":"01122","volume":"S0091\u20136749","author":"D Tha\u00e7i","year":"2025","unstructured":"Tha\u00e7i D, Laquer V, Lynde C, Reich A, Soong W, Worm M, et al. Targeting IL-22RA1 with temtokibart: a novel approach in atopic dermatitis: phase 2a monotherapy study results. J Allergy Clin Immunol. 2025;S0091\u20136749(25):01122\u20134.","journal-title":"J Allergy Clin Immunol"},{"key":"1054_CR181","unstructured":"Weidinger S, et al. IL-22RA1 antagonism with temtokibart provides significant early and sustained improvements in atopic dermatitis: results from a phase 2b dose-finding trial. Presented at: 2025 European Academy of Dermatology and Venereology (EADV) Congress; September 17\u201320, 2025; Paris, France. Abstract LBA-321."},{"key":"1054_CR182","doi-asserted-by":"crossref","unstructured":"Del Duca E, et al. Temtokibart, an IL-22RA1 monoclonal antibody broadly dampens gene expression markers of activated immune pathways in atopic dermatitis: results from a phase 2b trial subgroup analysis. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025; September 17\u201320, 2025; Paris, France. Abstract LBA-325.","DOI":"10.1016\/j.jid.2025.09.259"},{"issue":"8","key":"1054_CR183","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585\u2013608.","journal-title":"Nat Rev Drug Discov"},{"issue":"6545","key":"1054_CR184","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1126\/science.abg1209","volume":"372","author":"U Brinkmann","year":"2021","unstructured":"Brinkmann U, Kontermann RE. Bispecific antibodies. Science. 2021;372(6545):916\u20137.","journal-title":"Science"},{"issue":"7","key":"1054_CR185","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","volume":"21","author":"ME Goebeler","year":"2024","unstructured":"Goebeler ME, Stuhler G, Bargou R. Bispecific and multispecific antibodies in oncology: opportunities and challenges. Nat Rev Clin Oncol. 2024;21(7):539\u201360.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1054_CR186","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","volume":"7","author":"S Jin","year":"2022","unstructured":"Jin S, Sun Y, Liang X, Gu X, Ning J, Xu Y, et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther. 2022;7(1):39.","journal-title":"Signal Transduct Target Ther"},{"key":"1054_CR187","doi-asserted-by":"crossref","unstructured":"Amash A, Volkers G, Farber P, Griffin D, Davison KS, Goodman A, et al. Developability considerations for bispecific and multispecific antibodies. mAbs. 2024;16(1):2394229.","DOI":"10.1080\/19420862.2024.2394229"},{"key":"1054_CR188","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-1-0716-3878-1_11","volume":"2810","author":"M Peltret","year":"2024","unstructured":"Peltret M, Schmid A, Duarte L, Mette R, Giovannini R, Bertschinger M. Expression of multispecific antibodies. Methods Mol Biol Clifton NJ. 2024;2810:161\u201380.","journal-title":"Methods Mol Biol Clifton NJ."},{"key":"1054_CR189","doi-asserted-by":"publisher","first-page":"1668931","DOI":"10.3389\/falgy.2025.1668931","volume":"6","author":"T Zhang","year":"2025","unstructured":"Zhang T, Liu Y, Liew PX, Zhang Y, Zhao Z. Advances of bispecific antibodies using\/application in dermatology: a review. Front Allergy. 2025;6:1668931.","journal-title":"Front Allergy."},{"key":"1054_CR190","unstructured":"Yellow Jersey Therapeutics AG. Evaluation of NM26-2198 in healthy subjects and in patients with moderate-to-severe atopic dermatitis (AD). Identifier NCT05859724. Published May 22, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05859724. Accessed 18 Nov 2025."},{"issue":"11","key":"1054_CR191","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.09.251","volume":"145","author":"HJA Hunter","year":"2025","unstructured":"Hunter HJA, Rissmann R, Vekovska K, Gardiner P, Herv\u00e9 C, Rastrick J, et al. 247 A first-in-patient 18-week study of galvokimig, a multispecific antibody-based therapeutic targeting interleukin (IL)-13, IL-17A, and IL-17F in participants with moderate-to-severe atopic dermatitis (AD). J Invest Dermatol. 2025;145(11):e70.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1054_CR192","volume":"4","author":"J Tietz","year":"2024","unstructured":"Tietz J, Gunde T, Warmuth S, Weinert C, Brock M, Simonin A, et al. A bispecific, tetravalent antibody targeting inflammatory and pruritogenic pathways in atopic dermatitis. JID Innov Skin Sci Mol Popul Health. 2024;4(2):100258.","journal-title":"JID Innov Skin Sci Mol Popul Health."},{"issue":"1","key":"1054_CR193","first-page":"77","volume":"7","author":"F Deng","year":"2024","unstructured":"Deng F, Qiu Y, Zhang X, Guo N, Hu J, Yang W, et al. GB12-09, a bispecific antibody targeting IL4R\u03b1 and IL31R\u03b1 for atopic dermatitis therapy. Antib Ther. 2024;7(1):77\u201387.","journal-title":"Antib Ther."},{"key":"1054_CR194","unstructured":"Triple Beam Therapeutics, Inc. A study of PF-07275315 in subjects with moderate-to-severe atopic dermatitis (OMNI-AD). ClinicalTrials.gov Identifier: NCT05995964. https:\/\/clinicaltrials.gov\/study\/NCT05995964. Accessed 19 Nov 2025."},{"key":"1054_CR195","unstructured":"UCB Biopharma SRL. A phase I\/IIa, randomized, placebo-controlled, single-ascending-dose (Part A, participant- and investigator-blind) and repeated-dose (Part B, participant-, investigator-, and sponsor-blind) study to investigate the safety, pharmacokinetics, and efficacy of UCB9741 in healthy study participants (Part A) and in study participants with moderate-to-severe atopic dermatitis (Part B) (NCT04643457). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04643457. Accessed 20 Nov 2025."},{"issue":"12","key":"1054_CR196","doi-asserted-by":"publisher","first-page":"S270","DOI":"10.1016\/j.jid.2025.10.022","volume":"145","author":"S Stanyon","year":"2025","unstructured":"Stanyon S, Crosby A, Whittaker Z, Cherry H, Ferecsko A, Zaccheo O, et al. Galvokimig, a multispecific antibody\u2013based therapeutic, for the treatment of inflammatory skin diseases associated with both type 2 and type 3 inflammation. J Invest Dermatol. 2025;145(12):S270.","journal-title":"J Invest Dermatol"},{"key":"1054_CR197","unstructured":"Johnson & Johnson. Johnson & Johnson to obtain rights to a clinical-stage bispecific antibody to address distinct patient needs in atopic dermatitis. Press release, May 28, 2024. https:\/\/www.jnj.com\/media-center\/press-releases\/johnson-johnson-to-obtain-rights-to-a-clinical-stage-bispecific-antibody-to-address-distinct-patient-needs-in-atopic-dermatitis. Accessed 18 Nov 2025."},{"key":"1054_CR198","unstructured":"Bambusa Therapeutics, Inc. Bambusa therapeutics announces highly positive healthy volunteer results and first atopic dermatitis patient dosed in phase I trial of BBT001. PR Newswire. September 25, 2025. Available at: https:\/\/www.prnewswire.com\/news-releases\/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001-302567230.html. Accessed 19 Nov 2025."},{"key":"1054_CR199","unstructured":"Zai Lab Limited. Zai Lab presents new preclinical data for ZL-1503, an IL-13\/IL-31R bispecific antibody for the treatment of atopic dermatitis, at EAACI Congress 2025. Business Wire. June 13, 2025. https:\/\/zailab.gcs-web.com\/news-releases\/news-release-details\/zai-lab-presents-new-preclinical-data-zl-1503-il-13il-31r. Accessed 19 Nov 2025."},{"key":"1054_CR200","unstructured":"Johnson & Johnson to acquire Proteologix, Inc. to lead in atopic dermatitis treatment. Johnson & Johnson Media Center. May 16, 2024. https:\/\/www.jnj.com\/media-center\/press-releases\/johnson-johnson-to-acquire-proteologix-inc-to-lead-in-atopic-dermatitis-treatment. Accessed 19 Nov 2025."},{"key":"1054_CR201","unstructured":"Sanofi. A study to investigate the efficacy and safety of subcutaneous lunsekimig (SAR443765) compared with placebo in adult participants with moderate-to-severe atopic dermatitis. ClinicalTrials.gov Identifier: NCT06790121. https:\/\/clinicaltrials.gov\/study\/NCT06790121. Accessed 19 Nov 2025."},{"key":"1054_CR202","unstructured":"Janssen Research & Development, LLC. A study of JNJ-95475939 in the treatment of participants with moderate to severe atopic dermatitis (AD) (DUPLEX-AD). ClinicalTrials.gov identifier: NCT06881251. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06881251. Accessed 7 Mar 2026."},{"key":"1054_CR203","unstructured":"Johnson & Johnson. Johnson & Johnson statement on the Phase 2b DUPLEX-AD study. December 26, 2025. Available at: https:\/\/www.jnj.com\/media-center\/press-releases\/johnson-johnson-statement-on-the-phase-2b-duplex-ad-study. Accessed 7 Mar 2026."},{"key":"1054_CR204","unstructured":"Pfizer Inc. Pfizer pipeline update. May 2024. Available at: https:\/\/cdn.pfizer.com\/pfizercom\/product-pipeline\/Pipeline_Update_01MAY2024.pdf. Accessed 19 Nov 2025."},{"issue":"4","key":"1054_CR205","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.coph.2012.06.008","volume":"12","author":"A Kontzias","year":"2012","unstructured":"Kontzias A, Kotlyar A, Laurence A, Changelian P, O\u2019Shea JJ. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol. 2012;12(4):464\u201370.","journal-title":"Curr Opin Pharmacol"},{"issue":"10290","key":"1054_CR206","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet Lond Engl. 2021;397(10290):2151\u201368.","journal-title":"Lancet Lond Engl."},{"issue":"10246","key":"1054_CR207","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2020;396(10246):255\u201366.","journal-title":"Lancet Lond Engl."},{"issue":"2","key":"1054_CR208","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40257-023-00837-w","volume":"25","author":"RW Kim","year":"2024","unstructured":"Kim RW, Lam M, Abuabara K, Simpson EL, Drucker AM. Targeted systemic therapies for adults with atopic dermatitis: selecting from biologics and JAK inhibitors. Am J Clin Dermatol. 2024;25(2):179\u201393.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1054_CR209","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.jaci.2023.07.010","volume":"152","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Irvine AD, Brunner PM, Kim BS, Boguniewicz M, Parmentier J, et al. The role of Janus kinase signaling in the pathology of atopic dermatitis. J Allergy Clin Immunol. 2023;152(6):1394\u2013404.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"1054_CR210","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/rheumatology\/keu035","volume":"53","author":"HL Wright","year":"2014","unstructured":"Wright HL, Cross AL, Edwards SW, Moots RJ. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatol Oxf Engl. 2014;53(7):1321\u201331.","journal-title":"Rheumatol Oxf Engl."},{"issue":"7","key":"1054_CR211","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1001\/jamadermatol.2025.0982","volume":"161","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Gooderham M, Yang B, Wu J, Wu L, Loo WJ, et al. Ivarmacitinib for moderate to severe atopic dermatitis in adults and adolescents: a phase 3 randomized clinical trial. JAMA Dermatol. 2025;161(7):688\u201397.","journal-title":"JAMA Dermatol"},{"key":"1054_CR212","unstructured":"Zhang JZ, Yang B, Zhang X, et al. Efficacy and safety of LNK01001, a highly selective janus kinase 1 inhibitor, in chinese patients with moderate to severe atopic dermatitis: results from a randomized, double-blind, placebo-controlled phase 2 study. Presented at: 33rd EADV Congress; September 25\u201328, 2024; Amsterdam, Netherlands. Abstract 251. Accessed 14 Dec 2025."},{"key":"1054_CR213","unstructured":"Zhang J-Z, Lu Q-J, Gao X-H, et al. Efficacy and safety of Jaktinib, a novel JAK inhibitor in the treatment of patients with moderate to severe atopic dermatitis: a randomized, double-blind, placebo-controlled phase II study. Presented at: 32nd EADV Congress; October 11\u201314, 2023; Berlin, Germany. Abstract 1334. https:\/\/s3.eu-central-1.amazonaws.com\/m-anage.com.storage.eadv\/abstracts_congress2023\/34061.pdf. Accessed 14 Dec 2025."},{"issue":"9","key":"1054_CR214","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s40265-025-02202-z","volume":"85","author":"SJ Keam","year":"2025","unstructured":"Keam SJ. Ivarmacitinib sulfate: first approval. Drugs. 2025;85(9):1163\u201370.","journal-title":"Drugs"},{"issue":"1","key":"1054_CR215","doi-asserted-by":"publisher","first-page":"2591478","DOI":"10.1080\/09546634.2025.2591478","volume":"36","author":"Q Diao","year":"2025","unstructured":"Diao Q, Jia R, Li M, Zhao P, Lu F, Zhang Q, et al. Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial. J Dermatol Treat. 2025;36(1):2591478.","journal-title":"J Dermatol Treat"},{"key":"1054_CR216","doi-asserted-by":"crossref","unstructured":"Xiong F, Zhou B, Huang S, Li J, Cao Q, Jiang M, et al. Ivarmacitinib provides rapid and continuous improvement in patients with moderate-to-severe atopic dermatitis: a focus on different anatomical regions. Inflammopharmacology. 2026;34(1):797-804.","DOI":"10.1007\/s10787-025-02086-1"},{"issue":"5","key":"1054_CR217","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.063","volume":"89","author":"C Zhou","year":"2023","unstructured":"Zhou C, Yang X, Yang B, Yan G, Dong X, Ding Y, et al. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata. J Am Acad Dermatol. 2023;89(5):911\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"1054_CR218","unstructured":"Lynk Pharmaceuticals Co. A phase 3 study of LNK01001 capsule in subjects with moderate to severe atopic dermatitis. ClinicalTrials.gov Identifier: NCT06277245. A randomized, double-blind, placebo-controlled trial comparing LNK01001 with placebo in adults with moderate to severe atopic dermatitis. Updated 2025. https:\/\/clinicaltrials.gov\/study\/NCT06277245. Accessed 14 Dec 2025."},{"key":"1054_CR219","unstructured":"Suzhou Zelgen Biopharmaceuticals Co. A phase III study of jaktinib in adults with moderate and severe atopic dermatitis. ClinicalTrials.gov Identifier: NCT05526222. Sponsored by Suzhou Zelgen Biopharmaceuticals Co., Ltd.; Phase 3, randomized, double-blind, placebo-controlled trial of jaktinib hydrochloride tablets in adults with moderate-to-severe atopic dermatitis. Updated December 11, 2024. https:\/\/clinicaltrials.gov\/study\/NCT05526222. Accessed 14 Dec 2025."},{"issue":"6575","key":"1054_CR220","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/380630a0","volume":"380","author":"K Shimoda","year":"1996","unstructured":"Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature. 1996;380(6575):630\u20133.","journal-title":"Nature"},{"issue":"1","key":"1054_CR221","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13223-022-00652-8","volume":"18","author":"X Li","year":"2022","unstructured":"Li X, Han Z, Wang F, Qiao J. The STAT6 inhibitor AS1517499 reduces the risk of asthma in mice with 2,4-dinitrochlorobenzene-induced atopic dermatitis by blocking the STAT6 signaling pathway. Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol. 2022;18(1):12.","journal-title":"Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol."},{"issue":"1","key":"1054_CR222","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaci.2024.05.006","volume":"154","author":"JE Gudjonsson","year":"2024","unstructured":"Gudjonsson JE, Weidinger S, Kabashima K. The coming of age of protein degraders as anti-inflammatory therapeutics. J Allergy Clin Immunol. 2024;154(1):76\u20138.","journal-title":"J Allergy Clin Immunol"},{"key":"1054_CR223","doi-asserted-by":"crossref","unstructured":"Wang A, Yang B, Ramanathan A, Hossain A, Dong H, Follows B, et al. 53901 Potent and selective oral STAT6 degraders inhibit IL-4 and IL-13 functions in human cells and block TH2 inflammation in a mouse model of atopic dermatitis. J Am Acad Dermatol. 2024;91(3):AB282.","DOI":"10.1016\/j.jaad.2024.07.1122"},{"issue":"1","key":"1054_CR224","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175265","volume":"134","author":"H Yoon","year":"2024","unstructured":"Yoon H, Rutter JC, Li YD, Ebert BL. Induced protein degradation for therapeutics: past, present, and future. J Clin Invest. 2024;134(1):e175265.","journal-title":"J Clin Invest"},{"key":"1054_CR225","unstructured":"Kymera Therapeutics, Inc. First-in-human study of orally administered KT-621 in healthy adult participants (NCT06673667). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06673667. Updated September 29, 2025. Accessed 20 Nov 2025."},{"key":"1054_CR226","unstructured":"Recludix Pharma. Recludix Pharma announces development candidate nomination of first-in-class oral STAT6 inhibitor for inflammatory diseases and achievement of significant milestone under collaboration with Sanofi. Press release, San Diego, CA, June 2 2025. Available at: https:\/\/recludixpharma.com\/recludix-pharma-announces-development-candidate-nomination-of-first-in-class-oral-stat6-inhibitor-for-inflammatory-diseases-and-achievement-of-significant-milestone-under-collaboration-with-sanofi\/. Accessed 21 Nov 2025."},{"key":"1054_CR227","unstructured":"Johnson & Johnson. Johnson & Johnson to license novel oral assets, further strengthening commitment to atopic dermatitis. Press release, New Brunswick, NJ, December 26 2024. Available at: https:\/\/www.jnj.com\/media-center\/press-releases\/johnson-johnson-to-license-novel-oral-assets-further-strengthening-commitment-to-atopic-dermatitis. Accessed 21 Nov 2025."},{"key":"1054_CR228","unstructured":"Nurix Therapeutics, Inc. Sanofi exercises license-extension option to Nurix\u2019s STAT6 program. San Francisco: Nurix Therapeutics, Inc.; 02 June 2025. Available from: https:\/\/ir.nurixtx.com\/news-releases\/news-release-details\/sanofi-exercises-license-extension-option-nurixs-stat6-program\/. Accessed 21 Nov 2025."},{"issue":"6","key":"1054_CR229","doi-asserted-by":"publisher","first-page":"s712","DOI":"10.25251\/t4cqj323","volume":"9","author":"A Shabbir","year":"2025","unstructured":"Shabbir A, Agarwal S, McDonald A, Shi K, Conery A, Mortezavi M, et al. KT-621, an oral, once daily, targeted STAT6 degrader: first-in-human phase 1a safety, pharmacokinetics, pharmacodynamics and Th2 biomarker effects. SKIN J Cutan Med. 2025;9(6):s712\u2013s712.","journal-title":"SKIN J Cutan Med."},{"key":"1054_CR230","unstructured":"Kymera Therapeutics, Inc. A Phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose-ranging study with an open-label period investigating the efficacy and safety profile of KT-621 administered orally to participants with moderate to severe atopic dermatitis (NCT07217015). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT07217015. Updated October 15, 2025. Accessed 20 Nov 2025."},{"issue":"5","key":"1054_CR231","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/j.1398-9995.2008.01889.x","volume":"64","author":"MA Tewfik","year":"2009","unstructured":"Tewfik MA, Boss\u00e9 Y, Lemire M, Hudson TJ, Vall\u00e9e-Smejda S, Al-Shemari H, et al. Polymorphisms in interleukin-1 receptor-associated kinase 4 are associated with total serum IgE. Allergy. 2009;64(5):746\u201353.","journal-title":"Allergy"},{"issue":"12","key":"1054_CR232","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1038\/s41591-023-02635-7","volume":"29","author":"L Ackerman","year":"2023","unstructured":"Ackerman L, Acloque G, Bacchelli S, Schwartz H, Feinstein BJ, La Stella P, et al. IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial. Nat Med. 2023;29(12):3127\u201336.","journal-title":"Nat Med"},{"issue":"20","key":"1054_CR233","doi-asserted-by":"publisher","first-page":"18022","DOI":"10.1021\/acs.jmedchem.4c01305","volume":"67","author":"X Zheng","year":"2024","unstructured":"Zheng X, Ji N, Campbell V, Slavin A, Zhu X, Chen D, et al. Discovery of KT-474\u2500a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases. J Med Chem. 2024;67(20):18022\u201337.","journal-title":"J Med Chem"},{"key":"1054_CR234","doi-asserted-by":"crossref","unstructured":"Lavazais S, Jargosch M, Dupont S, Lab\u00e9gu\u00e8re F, Menet C, Jagerschmidt C, et al. IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases. Sci Transl Med. 2023;15(683):eabj3289.","DOI":"10.1126\/scitranslmed.abj3289"},{"issue":"2","key":"1054_CR235","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1021\/acs.jmedchem.3c01714","volume":"67","author":"U Bothe","year":"2024","unstructured":"Bothe U, G\u00fcnther J, Nubbemeyer R, Siebeneicher H, Ring S, B\u00f6mer U, et al. Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839. J Med Chem. 2024;67(2):1225\u201342.","journal-title":"J Med Chem"},{"issue":"11","key":"1054_CR236","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1007\/s13555-025-01505-z","volume":"15","author":"SJ Jodl","year":"2025","unstructured":"Jodl SJ, Worm M, Friedrichs F, Heinzel-Pleines U, Wagenfeld A, Feldm\u00fcller M, et al. Efficacy and safety of zabedosertib, an interleukin-1 receptor-associated kinase 4 inhibitor, in patients with moderate-to-severe atopic dermatitis: a phase II randomized study. Dermatol Ther. 2025;15(11):3329\u201345.","journal-title":"Dermatol Ther"},{"key":"1054_CR237","unstructured":"Nurix Therapeutics, Inc. Nurix Therapeutics presents preclinical data from novel IRAK4 degrader, GS-6791, demonstrating potent inhibition of IL-1 and IL-36 in vitro and efficacy in a model of dermatitis. Press release; September 17, 2025. Available from: https:\/\/ir.nurixtx.com\/news-releases\/news-release-details\/nurix-therapeutics-presents-preclinical-data-novel-irak4\/. Accessed 28 Nov 2025."},{"key":"1054_CR238","unstructured":"Kymera Therapeutics. KT-474 (SAR444656), a first in class IRAK4 degrader: Phase 1 clinical data in hidradenitis suppurativa and atopic dermatitis. Corporate press release; November 13, 2023. Available at: https:\/\/investors.kymeratx.com\/node\/9816\/pdf. Accessed 28 Nov 2025."},{"key":"1054_CR239","unstructured":"ClinicalTrials.gov. Phase 2 study of SAR444656 in adult participants with moderate to severe atopic dermatitis (ADVANTA). ClinicalTrials.gov Identifier: NCT06058156. Last updated December 11, 2025. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06058156. Accessed 27 May 2026."},{"key":"1054_CR240","unstructured":"ClinicalTrials.gov. LT-002-158: A phase 1 study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of LT-002-158 in healthy participants and patients with inflammatory skin disease. ClinicalTrials.gov Identifier: NCT06931990. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06931990. Accessed 28 Nov 2025."},{"key":"1054_CR241","unstructured":"Llapashtica C, Teng G, Huang Z, Mouchess M, Wu J, Barry V, Mohanan S, Mocciaro A, Schrier A, Palmer WS, Borodovsky A, Min-Oo G. IRAK4 degrader GS-6791 inhibits IL-1- and IL-36-driven responses in skin epithelial cells and demonstrates efficacy in a mouse model of dermatitis. Poster session presented at: 2025 EADV Congress; September 17-20, 2025; Publication by Gilead Sciences\/Nurix Therapeutics. Available at: https:\/\/www.nurixtx.com\/wp-content\/uploads\/2025\/09\/2025_03_11-GS-6791-EADV-2025-Poster_FinalDraft_GM_v2-4.pdf. Accessed 28 Nov 2025239."},{"issue":"1","key":"1054_CR242","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/exd.13808","volume":"28","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Hanifin JM, Boguniewicz M, Wollenberg A, Bissonnette R, Purohit V, et al. The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. Exp Dermatol. 2019;28(1):3\u201310.","journal-title":"Exp Dermatol"},{"issue":"1","key":"1054_CR243","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s10020-024-00906-8","volume":"30","author":"J Milara","year":"2024","unstructured":"Milara J, Ribera P, Mar\u00edn S, Montero P, Roger I, Cortijo J. Phosphodiesterase 4 is overexpressed in keloid epidermal scars and its inhibition reduces keratinocyte fibrotic alterations. Mol Med Camb Mass. 2024;30(1):134.","journal-title":"Mol Med Camb Mass."},{"key":"1054_CR244","doi-asserted-by":"crossref","unstructured":"Peter D, Jin SLC, Conti M, Hatzelmann A, Zitt C. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol Baltim Md 1950. 2007;178(8):4820\u201331.","DOI":"10.4049\/jimmunol.178.8.4820"},{"issue":"7","key":"1054_CR245","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cellsig.2016.01.007","volume":"28","author":"PH Schafer","year":"2016","unstructured":"Schafer PH, Truzzi F, Parton A, Wu L, Kosek J, Zhang LH, et al. Phosphodiesterase 4 in inflammatory diseases: effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4\/CD271 complex. Cell Signal. 2016;28(7):753\u201363.","journal-title":"Cell Signal"},{"key":"1054_CR246","unstructured":"ClinicalTrialsArena. Union plans phase III trial for atopic dermatitis after phase IIb win. ClinicalTrialsArena. Published [date of publication]. https:\/\/www.clinicaltrialsarena.com\/news\/union-plans-phase-iii-trial-for-atopic-dermatitis-after-phase-iib-win\/. Accessed 9 Dec2025."},{"issue":"6","key":"1054_CR247","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/bjd\/ljae507","volume":"192","author":"JI Silverberg","year":"2025","unstructured":"Silverberg JI, Eichenfield LF, Blauvelt A, Irvine AD, Guttman-Yassky E, Langley RG, et al. Orismilast, a phosphodiesterase 4B\/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS). Br J Dermatol. 2025;192(6):995\u20131006.","journal-title":"Br J Dermatol"},{"key":"1054_CR248","doi-asserted-by":"publisher","unstructured":"Li J, Cao B, Yang Y, Huang L, Ma T. First-in-human phase I trial: the safety, tolerability, and pharmacokinetics of HSK44459 in healthy subjects. Eur Respir J. 66(suppl 69):PA1841. https:\/\/doi.org\/10.1183\/13993003.congress-2025.PA1841.","DOI":"10.1183\/13993003.congress-2025.PA1841"},{"key":"1054_CR249","unstructured":"ClinicalTrials.gov. A phase II efficacy and safety study of HSK44459 in subjects with moderate to severe plaque psoriasis. Identifier: NCT07150988. https:\/\/clinicaltrials.gov\/study\/NCT07150988. Accessed 10 Dec 2025."},{"key":"1054_CR250","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety of HSK44459 in subjects with beh\u00e7et\u2019s disease. Identifier: NCT07070739. https:\/\/clinicaltrials.gov\/study\/NCT07070739. Accessed 10 Dec 2025."},{"key":"1054_CR251","unstructured":"ClinicalTrials.gov. A phase II study of HSK44459 in adults with moderate-to-severe plaque psoriasis. Identifier: NCT07019090. https:\/\/clinicaltrials.gov\/study\/NCT07019090. Accessed 10 Dec 2025."},{"key":"1054_CR252","unstructured":"Xizang Haisco Pharmaceutical Co., Ltd. ClinicalTrials.gov. 2025 [cited 2025 Oct 12]. A study for HSK44459 in participants with atopic dermatitis. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06996912."},{"issue":"4","key":"1054_CR253","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000067589","volume":"129","author":"Y Matsumoto","year":"2002","unstructured":"Matsumoto Y, Oshida T, Obayashi I, Imai Y, Matsui K, Yoshida NL, et al. Identification of highly expressed genes in peripheral blood T cells from patients with atopic dermatitis. Int Arch Allergy Immunol. 2002;129(4):327\u201340.","journal-title":"Int Arch Allergy Immunol"},{"issue":"1","key":"1054_CR254","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1600-0625.2010.01198.x","volume":"20","author":"A von Bonin","year":"2011","unstructured":"von Bonin A, Rausch A, Mengel A, Hitchcock M, Kr\u00fcger M, von Ahsen O, et al. Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases. Exp Dermatol. 2011;20(1):41\u20137.","journal-title":"Exp Dermatol"},{"issue":"2","key":"1054_CR255","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpet.2024.100054","volume":"392","author":"A Kaul","year":"2025","unstructured":"Kaul A, Hope H, Xu C, Basavalingappa R, Binz SK, Boily C, et al. Characterization of the dual ITK\/JAK3 small molecule covalent inhibitor ATI-2138. J Pharmacol Exp Ther. 2025;392(2):100054.","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"1054_CR256","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1111\/j.1742-4658.2011.08072.x","volume":"278","author":"J Gomez-Rodriguez","year":"2011","unstructured":"Gomez-Rodriguez J, Kraus ZJ, Schwartzberg PL. Tec family kinases Itk and Rlk\/Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates. FEBS J. 2011;278(12):1980\u20139.","journal-title":"FEBS J"},{"issue":"1","key":"1054_CR257","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.immuni.2004.06.009","volume":"21","author":"AT Miller","year":"2004","unstructured":"Miller AT, Wilcox HM, Lai Z, Berg LJ. Signaling through Itk promotes T helper 2 differentiation via negative regulation of T-bet. Immunity. 2004;21(1):67\u201380.","journal-title":"Immunity"},{"key":"1054_CR258","unstructured":"Available from: https:\/\/www.guidetoimmunopharmacology.org\/GRAC\/LigandDisplayForward?ligandId=14051."},{"key":"1054_CR259","doi-asserted-by":"crossref","unstructured":"Beaziz-Tordjman J, Del Duca E, Zhou J, Fiedler J, Estrada Y, Correa da Rosa J, et al. Molecular and clinical effects of oral ATI-2138, an ITK\/JAK3 inhibitor, in moderate-to-severe atopic dermatitis: a sub-study of a phase 2a open-label, single-arm trial. J Investig Dermatol. 2025.","DOI":"10.1016\/j.jid.2025.09.169"},{"key":"1054_CR260","unstructured":"ATI-2138. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: https:\/\/clinicaltrials.gov\/search?cond=ATI-2138. Accessed 12 Dec 2025."},{"issue":"1","key":"1054_CR261","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s44386-024-00002-1","volume":"1","author":"LY Hsu","year":"2024","unstructured":"Hsu LY, Rosenbaum JT, Verner E, Jones WB, Hill CM, Janc JW, et al. Synthesis and characterization of soquelitinib a selective ITK inhibitor that modulates tumor immunity. Npj Drug Discov. 2024;1(1):2.","journal-title":"Npj Drug Discov."},{"key":"1054_CR262","unstructured":"ClinicalTrials.gov. Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe atopic dermatitis. Identifier: NCT06345404. Updated 2025. https:\/\/clinicaltrials.gov\/study\/13\/12\/2025. Accessed 13 Dec 2025."},{"key":"1054_CR263","unstructured":"Corvus Pharmaceuticals, Inc. Corvus pharmaceuticals announces data from cohorts 1\u20133 of placebo-controlled phase 1 clinical trial of soquelitinib for atopic dermatitis. Press release. May 8, 2025. https:\/\/investor.corvuspharma.com\/news-releases\/news-release-details\/corvus-pharmaceuticals-announces-data-cohorts-1-3-placebo. Accessed 13 Dec 2025."},{"key":"1054_CR264","unstructured":"Enveda Therapeutics. Enveda initiates phase 2 clinical trials of ENV-294, a first-in-class oral therapy in atopic dermatitis and asthma. Business Wire. December 9, 2025. Available at: https:\/\/www.businesswire.com\/news\/home\/20251209287981\/en\/Enveda-Initiates-Phase-2-Clinical-Trials-of-ENV-294-a-First-in-Class-Oral-Therapy-in-Atopic-Dermatitis-and-Asthma. Accessed 7 Mar 2026."},{"issue":"1","key":"1054_CR265","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12964-024-01607-9","volume":"22","author":"A Doostmohammadi","year":"2024","unstructured":"Doostmohammadi A, Jooya H, Ghorbanian K, Gohari S, Dadashpour M. Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents. Cell Commun Signal CCS. 2024;22(1):228.","journal-title":"Cell Commun Signal CCS."},{"issue":"8","key":"1054_CR266","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41573-023-00735-0","volume":"22","author":"T Bieber","year":"2023","unstructured":"Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges. Nat Rev Drug Discov. 2023;22(8):662\u201380.","journal-title":"Nat Rev Drug Discov"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01054-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01054-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01054-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:06:05Z","timestamp":1789470365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01054-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":266,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1054"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01054-x","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EGY is an employee of Mount Sinai and has received research grants from and\/or is a consultant for Abbvie, Arcutis, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Apollo Therapeutics Limited, Artax Biopharma Inc., Aslan, Astria, Bristol Meyers Squibb, Boehringer-Ingelheim, Calliditas, Cara Therapeutics, Celldex, Centrexion Therapeutics Corporation, Concert, Connect Biopharm, Coty, DBV Technologies, Eli Lilly, Enveda Biosciences, Escient Pharmaceuticals, Inc., Fairmount Funds Management LLC, FL2022-001, Inc., Galderma, Gate Bio, Google Ventures (GV), GSK Immunology, Incyte, Imagene, Janssen Biotech, Jasper Therapeutics, Kymera Therapeutics, Kyowa Kirin, Leo Pharma, Matchpoint Therapeutics, Merck, Nektar Therapeutics, Novartis Pharmaceuticals, NUMAB Therapeutics AG, Nuvig, OrbiMed Advisors LLC, OTSUKA, Pfizer, Pharmaxis Ltd, Pioneering Medicine VII, Inc., Proteologix US Inc, Q32Bio, RAPT, RayThera, Inc, Regeneron Pharmaceuticals, RibonTherapeutics, Inc., SAGIMET Biosciences, Sanofi, SATO, Schr\u00f6dinger, Inc., Sitryx, Sun Pharma Advanced Research Company (SPARC), Takeda, Teva Branded Pharmaceutical Products R&D, Inc, TRex, UCB, Ventyx Biosciences. The rest of the authors declare that they have no relevant conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable to this article as no new data were created or analyzed in this study.","order":2,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GA, JB, FVM, KL outlined the article, performed the literature search, and drafted and revised the manuscript. EDD and EGY critically revised the work. All authors approved the final version of the manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}